Interchangeability of biosimilars - yes or no?
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: ROGER, Simon (Renal Research, Gosford, Australia)
The advent of biosimilars has followed the expiration of patents covering biopharmaceuticals, providing opportunities for pharmaceutical companies to develop, produce and market these biosimilars or follow-on biologicals. Switching patients from one product to a similar but [quotright]not quite identical[quotrightB]product may have important.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.